Diabetes is increasingly affecting children, necessitating early detection for effective management. Type 1, an autoimmune condition, appears suddenly, while Type 2, linked to obesity, develops ...

A U.S. senator said a GLP-1 drug changed his life — and now he's calling for widespread access to anti-obesity medications. In a New York Times op-ed on April 8, Sen. John Fetterman, D-Pa ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

“It’s really hard to tell whether it’s a personality change that can happen because of weight loss or if it’s a side effect because of mood changes,” he added.

New research released Thursday morning shows a new, oral GLP-1 pill may be just as beneficial to those with Type 2 diabetes as injectable GLP-1 drugs. Drugmaker Eli Lilly said that in Phase 3 ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Drugs in the same family as Ozempic and Wegovy are known for treating diabetes and helping with weight loss, but a small, early-stage study suggested they might also ease migraines -- even when ...

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and ...

Now, a study of 170,000 patient records suggests there’s a slightly lower risk of obesity-related cancers in U.S. adults with diabetes who took these popular medications compared to those who ...

The average representation of GLP-1 drugs used for weight loss in total annual claims was 10.5% for 2025, an increase over the 2024 average of 8.9% and the 2023 average of 6.9%.